Navigation Links
Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
Date:5/28/2008

0 YEARS OLD: RESULTS

OF A PHASE 1 STUDY

Abstract #0515

Poster session 2: Acute myeloid leukemia -- Clinical II

Saturday, June 14, 2008, 6:00 p.m. - 7:15 p.m. CEST

o A PHASE 1 TRIAL OF SNS-032, A POTENT AND SPECIFIC CDK 2, 7 AND 9

INHIBITOR, IN CHRONIC LYMPHOCYTIC LEUKEMIA AND MULTIPLE MYELOMA

Abstract #0792

Poster session 2: Novel therapies, drug resistance and pharmacology II

Saturday, June 14, 2008, 6:00 p.m. - 7:15 p.m. CEST

All clinical data presented will be available following each conference on the Sunesis corporate website at http://www.sunesis.com.

About Sunesis' Oncology Programs

Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell-cycle and survival signaling.

Sunesis' lead compound, voreloxin (formerly SNS-595), is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, irreversible G2 arrest and rapid apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients, in a Phase 1b clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, and as a single agent in a Phase 2 clinical trial in platinum-resistant ovarian cancer. In clinical trials conducted to date, voreloxin has been generally well tolerated and has shown objective responses in both solid and hematologic tumor types.

SNS-032, Sunesis' potent and selective inhibitor of cyclin-dependent kinases 2, 7 and 9, is being evaluated in a Phase 1 clinical trial in chronic lymphocytic leuke
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
4. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
5. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 /PRNewswire-iReach/ -- Today leading ... all new data ranking Pharmaceutical web sites for usability, ... Sciences, User Experience Cloud platform, which compares how people ... on the web. The top three performers ... convert people overall. The bottom performers have usability problems, ...
(Date:6/19/2013)... 19, 2013 /PRNewswire-iReach/ -- In its first ... pharmaceutical company dedicated to advancing development of ... sustained release drug therapies in patient disease ... announced the acquisition of Enzon Pharmaceutical,s PEGylation ... associated product pipeline. Acquisition of this technology ...
(Date:6/19/2013)... 19, 2013  Omnicell, Inc. (NASDAQ: ... supply management solutions and analytics software for healthcare ... number one overall pharmacy equipment vendor in the ... a leading independent healthcare research firm, compared the ... its annual rankings. Omnicell also received the prestigious ...
Breaking Medicine Technology:Sunovion tops new Change Sciences User Experience Rankings for Pharmaceutical Industry while McNeil-PPC ranks worst overall 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 2Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 3Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 4
...   Unigene Laboratories, Inc. (OTCBB: UGNE), ... of peptide-based therapeutics, announced that Ashleigh Palmer, President and ... the Biotech Showcase™ 2012 in San Francisco, CA on ... p.m. ET).  Mr. Palmer,s presentation will include an overview of ...
... Md., Jan. 4, 2012 /PRNewswire-iReach/ -- ... pharmaceutical company focused exclusively in the HIV-1 therapeutic ... to provide medicinal chemistry services to support DFH ... maturation inhibitor drugs. Maturation inhibitors are a novel ...
Cached Medicine Technology:Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 9 2DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs 2DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs 3
(Date:6/19/2013)... TX (PRWEB) June 19, 2013 Walkingspree, ... nationwide, today announced the launch of its new Facebook ... to motivate and inspire participants to reach their program ... Walkingspree platform , Walkingspree clients are given more tools ... and member profile. , Corporate clients may choose whether ...
(Date:6/19/2013)... June 19, 2013 After investing efforts ... SizeItUp formally announced the launch of database ... van is the latest entry in the list of ... 2013. The completely redesigned 2012 Nissan NV is all ... and critics alike. , Provided with two high power ...
(Date:6/19/2013)... 19, 2013 Health insurance exchanges ... of managed care. As many as 20 million ... new state-based and federally operated marketplaces. With details ... benefits, and examples of premium rates and benefit ... business information publisher Atlantic Information Services’s (AIS) recently ...
(Date:6/19/2013)... 2013 Sudden cardiac arrest can strike anyone, ... an average of 5 minutes after cardiac arrest, but the ... This means that death is highly probable if an automated ... for use. In response to this dire reality, US Representative ... Lives Act (H.R. 2308) which would provide support for AED ...
(Date:6/19/2013)... Woburn, MA (PRWEB) June 19, 2013 ... brand of advanced carpet cleaning machines, including reliable ... highly ranked grout cleaning machine systems , ... the XTreme Power® XPH-5900I for auto detailing professionals. ... the 5000 series of Daimer® models, is ideal ...
Breaking Medicine News(10 mins):Health News:Walkingspree’s New Facebook Connectivity Boosts Accountability and Engagement 2Health News:Rim Fitments Expert, SizeItUp Comes Up With Database Integrations For The 2012 Nissan NV 2Health News:New Special Report Provides Comprehensive Overview of New Health Insurance Exchange Marketplaces 2Health News:AED.com Supports Automated External Defibrillator (AED) Legislation in Schools in US and UK 2Health News:Daimer Ships Carpet Cleaners for Car Detailing Steam Cleaner Tasks 2Health News:Daimer Ships Carpet Cleaners for Car Detailing Steam Cleaner Tasks 3
... for foreign markets and plans,Canadian rollout, ... (OTC,Bulletin Board: UKMA), a lifestyle multimedia and ... personal development, announced today that,its exclusive international ... Xflowsion DVD series at the Electronic,Retailer,s Association ...
... Determinations, WASHINGTON, Oct. 28 National ... Administration,s,new "Compassionate Allowances Process" for disability determinations, ... Before announcing this,proposal, Social Security held public ... information from experts. NPAF, in collaboration with ...
... could reduce the cost and time required for cancer ... 28 online issue of the Journal of the ... a multistep process that involves in vitro tests, animal ... Inadequately designed rodent studies have led to missteps and ...
... DURHAM, N.C. -- Popular cholesterol-busting drugs -- statins -- appear ... according to researchers in the Duke Prostate Center and the ... prevent prostate cancer growth or just mask it is not ... statins were less likely to develop advanced forms of prostate ...
... become a billion-dollar substitute for flying business people ... to make sound judgments about speakers being viewed ... in a journal of the Institute for Operations ... in the Field: A Heuristic Processing Model" is ...
... because it may worsen another is a treatment trade-off ... rather take part in, researchers at Yale School of ... Journal of the American Geriatrics Society . , ... least two chronic conditions, and 24 percent have four ...
Cached Medicine News:Health News:uKarma Reports Progress With International Distribution Agreement for Its Xflowsion DVD Series 2Health News:National Patient Advocate Foundation (NPAF) Commends SSA's New 'Compassionate Allowances Process' 2Health News:Cholesterol-lowering drugs may also lower PSA, but whether they cut cancer risk is still not known 2Health News:Videoconferencing more confusing for decision-makers than face-to-face meetings 2Health News:Elderly fare better when included in decisions on treatment trade-offs 2
Fenestrated 14 mm blades. Wide extension of blade for protection of lids. Self-locking mechanism. Dull finish....
Solid 16 mm blades. Self-locking mechanism. Dull finish....
Infant model. Blades: 7 mm. Solid blades with locking mechanism. Dull finish....
Fenestrated 16 mm blades. Self-locking mechanism. Dull finish....
Medicine Products: